Study to Evaluate the Safety & Antipsoriatic Efficacy of BOS-475 in a

Clinical Trial Description

This is a three-center, randomized, placebo- and comparator-controlled, double-blind for the Investigational Medicinal Products (IMPs), observer-blind for the controls, intraindividual comparison of all 6 treatments. ;

Study Design

See also
Status	Clinical Trial	Phase
Completed	`NCT03598790` - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3
Completed	`NCT00799877` - Chronic Plaque Psoriasis (Ps) Registry
Completed	`NCT02581345` - Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis	Phase 3
Withdrawn	`NCT01200264` - Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy	Phase 2
Terminated	`NCT00972543` - Raptiva in Palm and Sole Psoriasis	Phase 4
Not yet recruiting	`NCT00707070` - Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis	Phase 4
Completed	`NCT00539929` - Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis	Phase 2
Completed	`NCT02852967` - A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis	Phase 2
Completed	`NCT00770965` - Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis	Phase 2
Active, not recruiting	`NCT06011733` - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis	Phase 3
Completed	`NCT00245765` - Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy	Phase 2
Completed	`NCT00673556` - A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate	Phase 3
Terminated	`NCT00844363` - Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris	N/A
Completed	`NCT00574249` - Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment	Phase 3
Completed	`NCT00512187` - Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial	Phase 4
Completed	`NCT02570750` - The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
Completed	`NCT00438360` - Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis	Phase 3
Active, not recruiting	`NCT03897075` - Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis	Phase 3
Completed	`NCT01358578` - Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis	Phase 3
Completed	`NCT03536884` - A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3

NCT number	NCT04221906
Study type	Interventional
Source	Boston Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	January 6, 2020
Completion date	March 6, 2020

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms